Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Beyond Air, Inc. (XAIR : NSDQ)

• Company Description    Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company. It is engaged in developing a Nitric Oxide Generator and Delivery System. The company's principal product is AirNOvent which is in clinical stage. Beyond Air Inc., formerly known as AIT Therapeutics Inc., is based in Garden City, New York. Number of Employees: 61

• Price / Volume Information    Yesterday's Closing Price: $0.70 Daily Weekly Monthly 20 Day Moving Average: 131,476 shares Shares Outstanding: 8.01 (millions) Market Capitalization: $5.64 (millions) Beta: 0.30 52 Week High: $10.40 52 Week Low: $0.67 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -40.79% -41.59% 12 Week -71.82% -72.49% Year To Date -90.17% -91.63%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 900 STEWART AVENUE SUITE 301 - GARDEN CITY,NY 11530 USA ph: 516-665-8200 fax: - ir@beyondair.net http://www.beyondair.net

• General Corporate Information    Officers Steven Lisi - Chairman and Chief Executive Officer Michael Gaul - Chief Operating Officer Douglas Q. Larson - Chief Financial Officer Robert S. Goodman - Director Erick J. Lucera - Director Peer Information Beyond Air, Inc. (CORR.) Beyond Air, Inc. (RSPI) Beyond Air, Inc. (CGXP) Beyond Air, Inc. (BGEN) Beyond Air, Inc. (GTBP) Beyond Air, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 08862L202 SIC: 3841 Fiscal Year Fiscal Year End: March Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/09/26 Share - Related Items Shares Outstanding: 8.01 Most Recent Split Date: 7.00 (0.05:1) Beta: 0.30 Market Capitalization: $5.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.43 Price/Cash Flow: - Price / Sales: 0.97 EPS Growth vs. Year Ago Period: 77.68% vs. Previous Quarter: 18.30% Sales Growth vs. Year Ago Period: 127.82% vs. Previous Quarter: 3.30% ROE 09/30/25 - -261.08 06/30/25 - -232.61 03/31/25 - -233.96 ROA 09/30/25 - -119.07 06/30/25 - -115.92 03/31/25 - -113.92 Current Ratio 09/30/25 - 4.24 06/30/25 - 3.24 03/31/25 - 3.20 Quick Ratio 09/30/25 - 3.73 06/30/25 - 2.71 03/31/25 - 2.72 Operating Margin 09/30/25 - -632.51 06/30/25 - -880.72 03/31/25 - -1,258.46 Net Margin 09/30/25 - -632.51 06/30/25 - -880.72 03/31/25 - -1,258.46 Pre-Tax Margin 09/30/25 - -650.31 06/30/25 - -909.70 03/31/25 - -1,308.47 Book Value 09/30/25 - 1.65 06/30/25 - 2.24 03/31/25 - 3.32 Inventory Turnover 09/30/25 - 2.62 06/30/25 - 2.44 03/31/25 - 2.21 Debt-to-Equity 09/30/25 - 0.77 06/30/25 - 0.92 03/31/25 - 0.64 Debt-to-Capital 09/30/25 - 43.51 06/30/25 - 48.03 03/31/25 - 39.07

Powered by Zacks Investment Research ©